Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

• Autor(a) principal: Aguiar, Pedro Nazareth
• Data de Publicação: 2017
• Outros Autores: De Mello, Ramon Andrade, Noia Barreto, Carmelia Maria, Perry, Luke Alastair, Penny-Dimri, Jahan, Tadokoro, Hakaru, Lopes, Gilberto de Lima
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.1/11148
• topic: Updated survival analysis; Randomized phase-Iii; Pd-L1 expression; Open-label; Maintenance bevacizumab; Predictive biomarker; Comparing cisplatin; Antitumor-activity; Next-generation; Stage Iiib

Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of nonsmall cell lung cancer (NSCLC) after failure of platinumbased therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.